Cerevel Therapeutics Holdings Performance
The firm shows a Beta (market volatility) of -0.19, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Cerevel Therapeutics are expected to decrease at a much lower rate. During the bear market, Cerevel Therapeutics is likely to outperform the market. Cerevel Therapeutics right now shows a risk of 0.0%. Please confirm Cerevel Therapeutics treynor ratio, as well as the relationship between the downside variance and kurtosis , to decide if Cerevel Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cerevel Therapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Cerevel Therapeutics is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 892 M |
Cerevel |
Cerevel Therapeutics Relative Risk vs. Return Landscape
If you would invest (100.00) in Cerevel Therapeutics Holdings on August 30, 2024 and sell it today you would earn a total of 100.00 from holding Cerevel Therapeutics Holdings or generate -100.0% return on investment over 90 days. Cerevel Therapeutics Holdings is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Cerevel, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cerevel Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cerevel Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cerevel Therapeutics Holdings, and traders can use it to determine the average amount a Cerevel Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CERE |
Based on monthly moving average Cerevel Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cerevel Therapeutics by adding Cerevel Therapeutics to a well-diversified portfolio.
Cerevel Therapeutics Fundamentals Growth
Cerevel Stock prices reflect investors' perceptions of the future prospects and financial health of Cerevel Therapeutics, and Cerevel Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cerevel Stock performance.
| Return On Equity | -0.92 | |||
| Return On Asset | -0.3 | |||
| Current Valuation | 7.71 B | |||
| Shares Outstanding | 182.2 M | |||
| Price To Earning | (0.26) X | |||
| Price To Book | 14.51 X | |||
| EBITDA | (441.64 M) | |||
| Cash And Equivalents | 531.21 M | |||
| Cash Per Share | 3.58 X | |||
| Total Debt | 480.78 M | |||
| Debt To Equity | 0.20 % | |||
| Book Value Per Share | 3.10 X | |||
| Cash Flow From Operations | (342.3 M) | |||
| Earnings Per Share | (2.73) X | |||
| Total Asset | 1.24 B | |||
| Retained Earnings | (1.4 B) | |||
| Current Asset | 9.77 M | |||
| Current Liabilities | 5.22 M | |||
About Cerevel Therapeutics Performance
By analyzing Cerevel Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Cerevel Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cerevel Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cerevel Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts. Cerevel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 258 people.Things to note about Cerevel Therapeutics performance evaluation
Checking the ongoing alerts about Cerevel Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cerevel Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cerevel Therapeutics is not yet fully synchronised with the market data | |
| Cerevel Therapeutics has some characteristics of a very speculative penny stock | |
| Cerevel Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (432.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cerevel Therapeutics Holdings currently holds about 531.21 M in cash with (342.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.58. | |
| Over 85.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Cerevel Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cerevel Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Cerevel Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cerevel Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cerevel Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cerevel Therapeutics' stock. These opinions can provide insight into Cerevel Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Cerevel Stock
If you are still planning to invest in Cerevel Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cerevel Therapeutics' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |